OTIC - Otonomy, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.6500
+0.1100 (+3.11%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.5400
Open3.5500
Bid3.6100 x 800
Ask3.9200 x 900
Day's Range3.4400 - 3.8000
52 Week Range1.9400 - 4.1800
Volume161,652
Avg. Volume158,808
Market Cap112.238M
Beta (5Y Monthly)2.73
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Otonomy Provides Corporate and Product Pipeline Update

    Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided an update on its product pipeline and financial guidance. Consistent with previously stated timing, the company expects to have results for the Phase 3 trial of OTIVIDEX in Ménière’s disease in the third quarter of 2020, the Phase 1/2 trial of OTO-313 in tinnitus patients in the second quarter of 2020, and the Phase 1/2 trial of OTO-413 in patients with hearing loss in the second half of 2020. The company finished 2019 with approximately $61 million in cash, cash equivalents and short term investments and expects that its current capital is sufficient to fund operations through the three clinical trials and into 2021.

  • GlobeNewswire

    Otonomy to Participate in Two Upcoming Investor Conferences

    SAN DIEGO, Nov. 26, 2019 -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.

  • GlobeNewswire

    Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s diseaseBroadest pipeline in neurotology field expanded to include gene.

  • GlobeNewswire

    Otonomy to Report Third Quarter 2019 Financial Results and Provide Corporate Update

    SAN DIEGO, Oct. 29, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.

  • GlobeNewswire

    AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss

    GAINESVILLE, Fla. and CAMBRIDGE, Mass. and SAN DIEGO, Oct. 01, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human.

  • GlobeNewswire

    Otonomy to Present at the Cantor Global Healthcare Conference

    SAN DIEGO, Sept. 26, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.

  • GlobeNewswire

    Otonomy Initiating Phase 1/2 Clinical Trial of OTO-413 in Hearing Loss

    Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 1/2 clinical trial of OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF), in patients with hearing loss. “Recent scientific research in the neurotology field has demonstrated that damage or loss of synaptic connections between inner ear hair cells and spiral ganglion neurons, known as cochlear synaptopathy, is involved in the hearing difficulty that many people experience in a loud environment, and that this pathology may also play a role in age-related and noise-induced hearing loss,” said Andrea Vambutas, M.D., Director for the Center of Hearing & Balance at the New York Head & Neck Institute.

  • GlobeNewswire

    Otonomy Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    Clinical-stage programs on track with results expected from three trials in 2020Current capital funds operations into 2021 Conference call and webcast today at 4:30 p.m. EDT.

  • GlobeNewswire

    Otonomy to Report Second Quarter 2019 Financial Results and Provide Corporate Update

    SAN DIEGO, July 25, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.

  • GlobeNewswire

    Otonomy to Present at the Raymond James Life Sciences and MedTech Conference

    SAN DIEGO, June 12, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.

  • GlobeNewswire

    Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update

    OTO-313 Phase 1/2 trial in tinnitus initiated; results expected in first half of 2020OTIPRIO® co-promotion agreement completed with Glenmark TherapeuticsOTIVIDEX™ Phase 3 trial.

  • ACCESSWIRE

    Otonomy, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 6, 2019 / Otonomy, Inc. (NASDAQ: OTIC ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 6, 2019 at 4:30 PM Eastern Time. ...

  • PR Newswire

    Glenmark Therapeutics Expands Specialty Portfolio with OTIPRIO® Co-Promotion Agreement in the U.S. with Otonomy for Acute Otitis Externa Indication

    MAHWAH, N.J., May 2, 2019 /PRNewswire/ -- Glenmark Therapeutics Inc., USA, a wholly-owned subsidiary of Glenmark Holding SA., today announced a co-promotion agreement with Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. Glenmark Therapeutics is dedicated to developing and commercializing a franchise of branded products for Glenmark Pharmaceuticals and is focused in the areas of respiratory and dermatology. Ryaltris™ (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg]), formerly GSP 301 Nasal Spray, is the company's leading respiratory pipeline asset and currently under review with the U.S. Food and Drug Administration (FDA) as a treatment for seasonal allergic rhinitis in patients 12 years and older.

  • GlobeNewswire

    Otonomy Announces OTIPRIO® Co-Promotion Agreement with Glenmark Therapeutics for Acute Otitis Externa Indication

    Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the signing of a co-promotion agreement with Glenmark Therapeutics Inc., USA, a wholly-owned subsidiary of Glenmark Holding SA., which is dedicated to building and commercializing a franchise of branded products for Glenmark Pharmaceuticals focused in the areas of respiratory and dermatology. This agreement provides Glenmark Therapeutics with an exclusive right to promote OTIPRIO (ciprofloxacin otic suspension) to ear, nose and throat (ENT) physician offices in the United States and its territories for the treatment of acute otitis externa (AOE) in patients 6 months of age and older due to Pseudomonas aeruginosa and Staphylococcus aureus.

  • GlobeNewswire

    Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit

    SAN DIEGO, May 01, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.

  • GlobeNewswire

    Otonomy to Report First Quarter 2019 Financial Results and Provide Corporate Update

    Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2019 as well as provide a corporate update at 4:30 p.m. EDT on May 6, 2019. The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 8076448. A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days.

  • GlobeNewswire

    Otonomy Initiates Phase 1/2 Clinical Trial of OTO-313 in Tinnitus

    Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 1/2 clinical trial of OTO-313, a sustained-exposure formulation of the NMDA receptor antagonist gacyclidine, in patients with tinnitus. The randomized, double-blind, placebo-controlled Phase 1/2 study will include an initial safety cohort followed by an exploratory efficacy study that will enroll approximately 50 patients with subjective tinnitus. "Tinnitus is a common problem affecting millions of people,” said Susan Marenda King, M.D., Neurotologist and Otologist at the Ear Medical Group in San Antonio, and Clinical Professor at the University of Texas Health Science Center.

  • GlobeNewswire

    Otonomy Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

    OTIVIDEX™ Phase 3 trial in Ménière’s disease on track for results in first half 2020 OTO-313 Phase 1/2 trial in tinnitus expected to start in second quarter of 2019OTO-413 Phase.

  • GlobeNewswire

    Otonomy to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update

    SAN DIEGO, Feb. 25, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.

  • GlobeNewswire

    Analysis: Positioning to Benefit within Apache, A. O. Smith, Diamondback Energy, Maiden, Lands' End, and Otonomy — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire

    Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting

    Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for Research in Otolaryngology (ARO) 42nd Annual MidWinter Meeting, to be held February 9-13, in Baltimore. “Our multiple presentations at ARO demonstrate our broad pipeline in neurotology with data presented in support of our product candidates for Ménière’s disease, tinnitus, hearing loss and otoprotection," said Kathie Bishop, Ph.D., chief scientific officer of Otonomy.